Emendo Biotherapeutics scores $61 mln Series B
Emendo Biotherapeutics, a provider of synthetic biology to address untreatable diseases, has raised $61 million in Series B funding.
Emendo Biotherapeutics, a provider of synthetic biology to address untreatable diseases, has raised $61 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination